Eli Lilly (LLY) stock sank on Thursday following the release of the pharmaceutical company’s Q2 2025 earnings report. That’s despite the company’s adjusted earnings per share of $6.31 and revenue of $15.56 billion. These were both above Wall Street’s estimates of $5.60 per share and revenue of $14.7 billion. Also, adjusted EPS increased 61% and revenue rose 38% year-over-year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Ricks, Chairman and CEO of Eli Lilly, said, “Lilly delivered another quarter of strong performance, achieving 38% year-over-year revenue growth driven by robust sales of Zepbound and Mounjaro and sustained momentum across our key medicines.”
LLY stock was down 7.35% in pre-market trading on Thursday, following a 2.56% drop yesterday. The shares have also decreased 2.96% year-to-date and 11.7% over the past 12 months. Pre-market trading had some 1.3 million shares exchanged, compared to a three-month daily average of about 3.2 million units.
Eli Lilly Guidance
Eli Lilly increased its guidance for 2025 in its latest earnings report. The company expects adjusted EPS to range from $21.75 to $23 on revenue between $60 billion and $62 billion. To put that in perspective, Wall Street estimates include adjusted EPS of $21.98 and revenue of $60.09 billion. With midpoints of $22.38 for EPS and $61 billion for revenue, Eli Lilly is on track to surpass analysts’ full-year 2025 estimates.
Unfortunately for Eli Lilly shareholders, the company also released clinical trial data for weight loss pill orforglipron today. The highest dosage resulted in a 12.4% drop in body fat, which met the primary endpoint but was below expectations. This news sent LLY shares lower despite today’s strong earnings results.
Is Eli Lilly Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Eli Lilly is Strong Buy, based on 17 Buy and three Hold ratings over the past three months. With that comes an average LLY stock price target of $1,016.69, representing a potential 36.22% upside for the shares. These ratings and price targets will likely change as analysts update their coverage after today’s earnings report.
